Instruction for use: Caverject

Dosage Form: lyophilisate for solution for intracavernous introduction

Active substance:

Alprostadil * (Alprostadilum)

ATX

C01EA01 Alprostadil

Pharmacotherapeutic group:

Vasodilating agent, a drug PGE2 [Prostaglandins, thromboxanes, leukotrienes and their antagonists]

Composition and release form

Alprostadil - 10 mcg and 20 mcg

in vials of 10 mg or 20, complete with a syringe filled with a solvent, and two needles; 1 set in a box.

Pharmacology

Mode of action - vasodilating, stimulates potency.

Dosage and Administration

Intracavernous. Dissolve contents of one vial of lyophilizate Vazaprostana® (corresponding to 20 mg of alprostadil) in 50 mL of saline.

In the absence of other requirements Vazaprostan® half of the vial (equivalent to 10 mcg alprostadil) introducing / and for 60-120 minutes using an infusion device. If necessary, especially in the presence of necrosis, under the strict control of tolerance may increase the dose to 20 mcg alprostadil (the contents of 1 ampoule). This dosage is typically used for a single daily infusion.

If Intraarterial and injected through an infusion catheter is performed, depending on the severity of the disease and tolerability recommended dose of 0.1-0.6 ng / kg / min with the introduction of the drug for 12 hours using an infusion device (corresponds to 0,25- 1.5 ampoules vazaprostan).

intraarterial. Dissolve contents of two vials lyophilizate Vazaprostana® (corresponds to 40 .mu.g of alprostadil) in 50-250 ml of physiological saline and the resulting solution is introduced into / in 2 for 2 hours twice a day or three capsules (60 mg of alprostadil) for 3 times at 1 hr day.

Patients with impaired kidney function (renal failure with a creatinine level greater than 1.5 mg / dL) in / with the introduction begins with 20 micrograms for 2 hours. If necessary, after 2-3 days of a single dose of 40-60 mg.

For patients with heart failure and renal maximum volume of fluid injected - 50-100 ml / day. The course of treatment - 4 weeks.

Duration of treatment - 14 days on average, with a positive effect of drug treatment can continue for a further 7-14 days. In the absence of a positive effect within 2 weeks of starting treatment continued use of the drug should be discontinued.

Preparation of the solution. To prepare the solution should be immediately before the infusion. Lyophilisate dissolves immediately after the addition of saline. At the beginning of the solution can turn a milky-cloudy. This effect is created by air bubbles and has no value. After a short time the solution becomes clear. Do not use a solution prepared more than 12 hours ago.

Storage conditions of the drug Caverject

The temperature is not above 25 ° C. Do not freeze.

Keep out of the reach of children.

Shelf lifeof Caverject

2 years.

Do not use beyond the expiration date printed on the package.